Supernus Pharmaceuticals (LTS:0LB2) YoY EBITDA Growth: -175.86% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $43.20
GF Value $44.24
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Supernus Pharmaceuticals YoY EBITDA Growth?

Supernus Pharmaceuticals LTS:0LB2 -0.34% 88 YoY EBITDA Growth is -175.86% as of Jun. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $44.24 (Fairly Valued). The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Supernus Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -175.86%.

Supernus Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2026 was $-0.51.

Supernus Pharmaceuticals YoY EBITDA Growth Related Terms

Supernus Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals YoY EBITDA Growth Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.38 4.59 -34.75 96.42 -76.37

Supernus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.01 -158.50 -58.26 10.06 -175.86
LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Supernus Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.753-3.186)/ | 3.186 |
=-76.37 %

Supernus Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.509-0.671)/ | 0.671 |
=-175.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -175.86% mean?
Supernus Pharmaceuticals (LTS:0LB2) has a YoY EBITDA Growth of -175.86% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' YoY EBITDA Growth too high?
Supernus Pharmaceuticals' current YoY EBITDA Growth is -175.86%. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' YoY EBITDA Growth compare to RGC and BCRX?
Supernus Pharmaceuticals' YoY EBITDA Growth of -175.86% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current YoY EBITDA Growth is -175.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $44.24, compared to a current price of $43.20 — trading 2.4% below its estimated fair value. The current YoY EBITDA Growth is -175.86%. Supernus Pharmaceuticals' overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current YoY EBITDA Growth is -175.86% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be undervalued. The current stock price of $43.20 is trading 2.4% below its estimated GF Value™ of $44.24. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LB2:

  • YoY EBITDA Growth: -175.86%
  • GF Value™: $44.24 vs. price of $43.20 (2.4% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.20
Price
$44.24
GF Value